Originally Posted by
wiggin
Pharma companies don't operate under normal rules, Tim. The reality is that most pharma companies (outside of generics houses) aren't selling interchangeable commodities, but each have unique and critical offerings that cannot be easily replaced. And furthermore, shortages of various drugs and devices have become a fact of life nowadays, victims of consolidation, regulation, and a lack of stockpiling. If anything goes wrong in a production process - and they do, from raw material shortages to microbial contamination to safety incidents to FDA letters - you might experience a global shortfall with little to no notice. And rarely will you have serious consequences for the company in question, outside of the occasional acquisition (as in the case of Sanofi acquiring Genzyme when they had serious production issues that made them a target).
The real consequences, of course, are to their bottom line - drugs and devices are high margin businesses, but also capital intensive. You lose vast sums of money when production is delayed, so they have every incentive to keep things going. For a low margin corner of the business like the vaccine world (especially for something that is ostensibly being sold at cost), those incentives become lower while the scale of capital necessary remains very high.
In normal ramp-up of production, you wouldn't go from zero to a billion doses in less than a year. That's crazy fast and will undoubtedly come with bottlenecks and setbacks. The timelines promised by these companies have generally been predicated on the assumption that everything goes right, an assumption we know will be violated.
The issue here probably has less to do with AZN's production failings or fail to deliver exactly what was promised. Their problem was probably a failure in managing expectations appropriately, including timely and transparent updates to the key stakeholders. This is a basic rule of sales and marketing and I suspect they did a bad job.